Brookmont Capital Management’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-5,720
| Closed | -$1.6M | – | 57 |
|
|
2025
Q2 | $1.6M | Sell |
5,720
-58
| -1% | -$16.4K | 0.92% | 29 |
|
|
2025
Q1 | $1.8M | Sell |
5,778
-235
| -4% | -$69.4K | 1.02% | 29 |
|
|
2024
Q4 | $1.57M | Sell |
6,013
-130
| -2% | -$38.6K | 0.84% | 31 |
|
|
2024
Q3 | $1.98M | Sell |
6,143
-180
| -3% | -$58.9K | 1.02% | 29 |
|
|
2024
Q2 | $1.98M | Sell |
6,323
-4,016
| -39% | -$1.18M | 1.08% | 29 |
|
|
2024
Q1 | $2.94M | Buy |
10,339
+90
| +0.9% | +$26.3K | 1.55% | 24 |
|
|
2023
Q4 | $2.95M | Sell |
10,249
-28
| -0.3% | -$7.63K | 1.65% | 23 |
|
|
2023
Q3 | $2.76M | Sell |
10,277
-57
| -0.6% | -$14.2K | 1.72% | 22 |
|
|
2023
Q2 | $2.29M | Buy |
10,334
+3
| +0% | +$696 | 1.38% | 26 |
|
|
2023
Q1 | $2.5M | Buy |
10,331
+28
| +0.3% | +$6.87K | 1.57% | 23 |
|
|
2022
Q4 | $2.71M | Sell |
10,303
-366
| -3% | -$98.1K | 1.66% | 22 |
|
|
2022
Q3 | $2.4M | Buy |
10,669
+634
| +6% | +$154K | 1.67% | 24 |
|
|
2022
Q2 | $2.44M | Sell |
10,035
-364
| -4% | -$89.2K | 1.68% | 22 |
|
|
2022
Q1 | $2.52M | Buy |
10,399
+70
| +0.7% | +$16.1K | 1.51% | 28 |
|
|
2021
Q4 | $2.32M | Sell |
10,329
-382
| -4% | -$80.6K | 1.23% | 29 |
|
|
2021
Q3 | $2.28M | Buy |
10,711
+160
| +2% | +$36.8K | 1.34% | 30 |
|
|
2021
Q2 | $2.57M | Sell |
10,551
-49
| -0.5% | -$12.1K | 1.56% | 25 |
|
|
2021
Q1 | $2.64M | Sell |
10,600
-142
| -1% | -$33.9K | 1.7% | 21 |
|
|
2020
Q4 | $2.47M | Sell |
10,742
-794
| -7% | -$183K | 1.74% | 18 |
|
|
2020
Q3 | $2.93M | Buy |
11,536
+192
| +2% | +$47.6K | 2.18% | 12 |
|
|
2020
Q2 | $2.68M | Sell |
11,344
-3,497
| -24% | -$798K | 2.14% | 13 |
|
|
2020
Q1 | $3.01M | Sell |
14,841
-1,228
| -8% | -$268K | 2.42% | 9 |
|
|
2019
Q4 | $3.87M | Sell |
16,069
-1,735
| -10% | -$382K | 2.31% | 10 |
|
|
2019
Q3 | $3.44M | Buy |
17,804
+314
| +2% | +$60.3K | 1.97% | 20 |
|
|
2019
Q2 | $3.22M | Buy |
17,490
+115
| +0.7% | +$20.6K | 1.94% | 22 |
|
|
2019
Q1 | $3.3M | Buy |
17,375
+24
| +0.1% | +$4.58K | 2.03% | 22 |
|
|
2018
Q4 | $3.38M | Sell |
17,351
-1,369
| -7% | -$267K | 2.3% | 12 |
|
|
2018
Q3 | $3.88M | Buy |
18,720
+13
| +0.1% | +$2.56K | 2.31% | 13 |
|
|
2018
Q2 | $3.45M | Buy |
18,707
+633
| +4% | +$112K | 2.17% | 15 |
|
|
2018
Q1 | $3.08M | Sell |
18,074
-13,652
| -43% | -$2.51M | 2.04% | 20 |
|
|
2017
Q4 | $5.52M | Buy |
31,726
+10,155
| +47% | +$1.8M | 2.38% | 25 |
|
|
2017
Q3 | $4.02M | Buy |
21,571
+148
| +0.7% | +$26.2K | 2.2% | 19 |
|
|
2017
Q2 | $3.69M | Sell |
21,423
-411
| -2% | -$66.8K | 1.39% | 27 |
|
|
2017
Q1 | $3.58M | Buy |
21,834
+14,382
| +193% | +$2.39M | 1.32% | 26 |
|
|
2016
Q4 | $1.09M | Sell |
7,452
-4,066
| -35% | -$612K | 0.43% | 34 |
|
|
2016
Q3 | $1.92M | Buy |
11,518
+194
| +2% | +$32.8K | 0.72% | 34 |
|
|
2016
Q2 | $1.72M | Sell |
11,324
-4,578
| -29% | -$712K | 0.63% | 35 |
|
|
2016
Q1 | $2.38M | Sell |
15,902
-2,177
| -12% | -$323K | 0.76% | 37 |
|
|
2015
Q4 | $2.94M | Buy |
18,079
+1,393
| +8% | +$219K | 0.83% | 37 |
|
|
2015
Q3 | $2.31M | Buy |
16,686
+259
| +2% | +$40.8K | 0.66% | 39 |
|
|
2015
Q2 | $2.52M | Buy |
16,427
+7,643
| +87% | +$1.22M | 0.64% | 42 |
|
|
2015
Q1 | $1.4M | Buy |
8,784
+5,502
| +168% | +$867K | 0.35% | 45 |
|
|
2014
Q4 | $523K | Buy |
+3,282
| New | +$511K | 0.15% | 50 |
|
Other funds holding AMGN
Brookmont Capital Management's AMGN Position: Q3 2025 in Review
Brookmont Capital Management sold out of Amgen (AMGN) in Q3 2025, closing a stake of 5,720 shares — an estimated $1.6M sold.
Brookmont Capital Management first reported a position in AMGN in Q4 2014 and held it in 43 quarters. The position peaked at $5.52M in Q4 2017. 2,820 funds tracked by Wall St. Rank hold AMGN as of Q3 2025.
- Brookmont Capital Management reported no remaining Amgen position as of Q3 2025 after selling out during the quarter.
- Brookmont Capital Management sold 5,720 Amgen shares in Q3 2025, an estimated $1.6M.
- Brookmont Capital Management first reported a position in Amgen in Q4 2014 and held it in 43 quarters.
- Brookmont Capital Management's Amgen position peaked at $5.52M in Q4 2017.
- 2,820 funds tracked by Wall St. Rank held Amgen as of Q3 2025.
Based on Brookmont Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.